Scientific Publications
22Jun, 2017
Clinical Effects Of Tramiprosate In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease Suggest Disease Modification Potential
S. Abushakra, A. Porsteinsson, P. Scheltens, C. Sadowsky, B. Vellas, J. Cummings, S. [...]
24Apr, 2017
Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data
Petr Kocis, Martin Tolar, Jeremy Yu, William Sinko, Soumya Ray, Kaj Blennow, Howard Fillit, John A. Hey Abstract Background Amyloid beta (Aβ) oligomers play a critical role in the [...]
29Mar, 2017
ALZ-801 Brain Penetration, PK/PD Analyses And Clinical Dose Projection Form The Basis For Confirmatory Phase 3 Study In Alzheimer’s Disease
Abstract OBJECTIVES: ALZ-801 is a novel prodrug of tramiprosate with improved pharmacokinetics (PK) [...]
29Mar, 2017
Tramiprosate Efficacy in APOE4 Homozygous Subjects with AD: Larger Effects in Mild Patient Subgroups
Abstract OBJECTIVES: ALZ-801 is an oral pro-drug of tramiprosate being developed as a [...]
9Dec, 2016
Phase 1 Program of ALZ-801, a Novel Prodrug of Tramiprosate with Improved Tolerability, Supports Bridging to Upcoming Phase 3 Program
Presented at the 9th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held [...]
28Oct, 2016
Clinical Benefits of Tramiprosate in Alzheimer’s Disease Are Associated with Higher Number of APOE4 Alleles: The “APOE4 Gene-Dose Effect”
S. Abushakra, A. Porsteinsson, B.Vellas, J. Cummings, S. Gauthier, J.A. Hey, A. Power, [...]